#ππ²ππππ«π ππ¦π¨π§π ππ‘π ππ‘π ππ¨π© πππ₯π₯π’π§π ππππ’ππ’π§ππ¬ π¨π ππ‘ππ«π¦π 2024
πͺ Great to see 2 #ophthalmic drugs made the list of top selling medicines for 2024 including Bayer with Eyelea and Roche Vabysmo.
π Bayer
Bayer, alongside Regeneron, co-markets Eyelea β a leading anti-VEGF therapy for age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. While not listed as their top seller, Eylea continues to dominate the retina market globally.
π Roche
Vabysmo (faricimab)βa bispecific antibody targeting both VEGF and Ang-2βhas been a game-changer in retinal disease. Launched as a challenger to Eylea, it has gained strong traction thanks to its dual-action and potential for extended dosing.
π While Novartisβwith Lucentis, a competitor to Eyleaβand AbbVie both have ophthalmic drugs in their pipelines, neither company saw them break into their top three bestsellers this year.
Graphic: Joanna Sadowska